Sperling Prostate Center

A New Paradigm in the Detection and Treatment of Prostate Cancer


Share infographic on your site:

< a href="https://sperlingprostatecenter.com/">Sperling Prostate Center


Depending on who you ask, the recommended age at which a man should begin regular prostate cancer screenings tends to skew between the ages of 40 and 50. For most men with an average risk, screenings usual begins at age 50. However, some doctors recommend that men at higher risks of prostate cancer – African American men or men who have a family history of prostate cancer – begin their screenings at age 40. Regardless of wherever one may land on this spectrum, the issue of moving forward after a Prostate-Specific Antigen (PSA) test yielding high results receives the same response: “What do I do next?”

Upon receiving news of high PSA levels, men generally only had one option moving forward: undergo an invasive transrectal ultrasound (TRUS); a procedure which places an ultrasound probe into the rectum, guiding the physician to problem sections of the prostate where they would then extract samples of the prostate using upwards of 24 hypodermic needles. Not only is this dated procedure painful and carries the risk of infection, the low quality ultrasound imagery being used is unreliable in detecting all possible tumors. What’s more, the options for treatment subsequent to diagnosis of prostate cancer carry a number of high risk elements of their own.

Fortunately, there is a better method for detecting prostate cancer post high PSA results: The Bluelaser 3T MP MRI. This revolutionary procedure uses the latest in MRI technology to produce high-definition 3D imagery of the prostate, allowing physicians to pinpoint exactly where a tumor, if any, is located on the prostate. Better yet, this procedure does not require any unnecessary probing and can be used across the entire prostate cancer detection, diagnosis and treatment process.

The following infographic candidly compares the more traditional approaches toward prostate cancer detection, diagnosis and treatment with the new innovations of the Bluelaser 3T MP MRI method. See how they all stack up against each other and become more informed when it comes to your options for prostate cancer detection and treatment.

About Dr. Dan Sperling

Dan Sperling, MD, DABR, is a board certified radiologist who is globally recognized as a leader in multiparametric MRI for the detection and diagnosis of a range of disease conditions. As Medical Director of the Sperling Prostate Center, Sperling Medical Group and Sperling Neurosurgery Associates, he and his team are on the leading edge of significant change in medical practice. He is the co-author of the new patient book Redefining Prostate Cancer, and is a contributing author on over 25 published studies. For more information, contact the Sperling Prostate Center.

WordPress Image Lightbox